DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
PFE logo

Pfizer Inc. Stock Price

NYSE:PFE Community·US$162.2b Market Cap
  • 6 Narratives written by author
  • 0 Comments on narratives written by author
  • 1192 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

PFE Share Price Performance

US$28.55
3.57 (14.29%)
​
US$29.19
Fair Value
US$28.55
3.57 (14.29%)
2.2% undervalued intrinsic discount
US$29.19
Fair Value
Price US$28.55
AnalystConsensusTarget US$29.19
Valrodmon US$28.00
AnalystHighTarget US$35.17
Mon, 25 May 26
Fair ValueUS$29.19
Share Pricen/a

PFE Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$29.19 2.2% undervalued intrinsic discount

Expanding Oncology Pipelines And Emerging Markets Will Unlock Future Success

6users have liked this narrative
1users have commented on this narrative
515users have followed this narrative
VA
Valrodmon
Valrodmon's
Fair Value
·
Fair Value US$28 2.0% overvalued intrinsic discount

Pfizer is about resilience and dividend yield

1users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$35.17 18.8% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Unlock New Opportunities

5users have liked this narrative
0users have commented on this narrative
60users have followed this narrative
PFE logo
Pfizer
2.0% overvalued intrinsic discount

Pfizer is about resilience and dividend yield

View narrative
VA
Valrodmon
Valrodmon
Published 31 Dec 2025
Read Narrative
PFE logo
Pfizer
6.8% undervalued intrinsic discount

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

View narrative
FR
Francisco
Published 4 Mar 2025
Read Narrative
PFE logo
Pfizer
14.2% overvalued intrinsic discount

Rising Regulatory Hurdles Will Undercut Pharmaceutical Profits Despite Pipeline Hope

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 5 Aug
Read Narrative
PFE logo
Pfizer
18.8% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Unlock New Opportunities

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 13 Jul
Read Narrative
PFE logo
Pfizer
2.2% undervalued intrinsic discount

Expanding Oncology Pipelines And Emerging Markets Will Unlock Future Success

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 25 May
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

VA
Valrodmon
PFE logo

Pfizer is about resilience and dividend yield

Fair Value: US$28 2.0% overvalued intrinsic discount
52 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
FR
PFE logo

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Fair Value: US$30.62 6.8% undervalued intrinsic discount
33 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
PFE logo

PFE: Pipeline Readouts And Legal Overhang Will Shape Post Covid Earnings Trajectory

Fair Value: US$25 14.2% overvalued intrinsic discount
20 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Established dividend payer with slight risk.

4 Risks
2 Rewards
View Full Analysis

Pfizer Inc. Key Details

US$63.7b

Revenue

US$16.1b

Cost of Revenue

US$47.6b

Gross Profit

US$43.3b

Other Expenses

US$4.3b

Earnings

Last Reported Earnings
Jun 28, 2026
Next Reporting Earnings
n/a
0.76
74.72%
6.81%
74.3%
View Full Analysis

About PFE

Founded
1849
Employees
75000
CEO
Albert Bourla
WebsiteView website
www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Recent PFE News & Updates

Recent updates

No updates

Pfizer Inc. Competitors

LLY logo

Eli Lilly

Symbol: NYSE:LLY
Market cap: US$1.0t
JNJ logo

Johnson & Johnson

Symbol: NYSE:JNJ
Market cap: US$640.7b
ABBV logo

AbbVie

Symbol: NYSE:ABBV
Market cap: US$453.1b
MRK logo

Merck

Symbol: NYSE:MRK
Market cap: US$364.5b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide